Peter A Cohen

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. ncbi CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection
    P A Cohen
    Center for Surgery Research, Cleveland Clinic Foundation, OH 44195, USA
    Crit Rev Immunol 20:17-56. 2000
  2. pmc STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells
    Peter A Cohen
    Center for Surgery Research, Cleveland Clinic Foundation Lerner Research Institute, OH 44195, USA
    Blood 112:1832-43. 2008
  3. ncbi T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance
    P A Cohen
    Center for Surgery Research, Cleveland Clinic Foundation, OH 44195, USA
    Crit Rev Immunol 21:215-48. 2001
  4. doi Effective treatment of spontaneous metastases derived from a poorly immunogenic murine mammary carcinoma by combined dendritic-tumor hybrid vaccination and adoptive transfer of sensitized T cells
    Hidemasa Tamai
    Center for Surgery Research NE62, Department of Immunology, Cleveland Clinic, Cleveland, 9500 Euclid Ave, Cleveland, OH 44195, USA
    Clin Immunol 127:66-77. 2008
  5. ncbi Significance of regional draining lymph nodes in the development of tumor immunity: implications for cancer immunotherapy
    Rongxiu Zheng
    Center for Surgery Research, Cleveland Clinic, Cleveland, Ohio, USA
    Cancer Treat Res 135:223-37. 2007
  6. ncbi Immunogenicity of dendritic-tumor fusion hybrids and their utility in cancer immunotherapy
    Suyu Shu
    Center for Surgery Research, NE6 307, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Crit Rev Immunol 27:463-83. 2007
  7. ncbi Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes
    Satoshi Watanabe
    Center for Surgery Research, Department of Immunology, Cleveland Clinic, Cleveland, OH 44195, USA
    J Immunol 181:3291-300. 2008
  8. doi Reengineering dendritic cell-based anti-cancer vaccines
    Gary K Koski
    Department of Immunology, Center for Surgery Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Immunol Rev 222:256-76. 2008
  9. ncbi Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor
    J Kjaergaard
    Center for Surgery Research and Lerner Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Immunol 167:6669-77. 2001
  10. ncbi Tumor-induced L-selectinhigh suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy
    Liaomin Peng
    Center for Surgery Research, Cleveland Clinic Foundation, and Lerner Research Institute, OH 44195, USA
    J Immunol 169:4811-21. 2002

Collaborators

Detail Information

Publications28

  1. ncbi CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection
    P A Cohen
    Center for Surgery Research, Cleveland Clinic Foundation, OH 44195, USA
    Crit Rev Immunol 20:17-56. 2000
    ....
  2. pmc STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells
    Peter A Cohen
    Center for Surgery Research, Cleveland Clinic Foundation Lerner Research Institute, OH 44195, USA
    Blood 112:1832-43. 2008
    ....
  3. ncbi T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance
    P A Cohen
    Center for Surgery Research, Cleveland Clinic Foundation, OH 44195, USA
    Crit Rev Immunol 21:215-48. 2001
    ....
  4. doi Effective treatment of spontaneous metastases derived from a poorly immunogenic murine mammary carcinoma by combined dendritic-tumor hybrid vaccination and adoptive transfer of sensitized T cells
    Hidemasa Tamai
    Center for Surgery Research NE62, Department of Immunology, Cleveland Clinic, Cleveland, 9500 Euclid Ave, Cleveland, OH 44195, USA
    Clin Immunol 127:66-77. 2008
    ..Taken together, the combined approach may be useful for clinical development of cancer immunotherapy...
  5. ncbi Significance of regional draining lymph nodes in the development of tumor immunity: implications for cancer immunotherapy
    Rongxiu Zheng
    Center for Surgery Research, Cleveland Clinic, Cleveland, Ohio, USA
    Cancer Treat Res 135:223-37. 2007
  6. ncbi Immunogenicity of dendritic-tumor fusion hybrids and their utility in cancer immunotherapy
    Suyu Shu
    Center for Surgery Research, NE6 307, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Crit Rev Immunol 27:463-83. 2007
    ....
  7. ncbi Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes
    Satoshi Watanabe
    Center for Surgery Research, Department of Immunology, Cleveland Clinic, Cleveland, OH 44195, USA
    J Immunol 181:3291-300. 2008
    ..Our data provide the first evidence that the systemic transfer of MDSC inhibited and interfered with the sensitization of tumor-specific T cell responses in the TDLN...
  8. doi Reengineering dendritic cell-based anti-cancer vaccines
    Gary K Koski
    Department of Immunology, Center for Surgery Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Immunol Rev 222:256-76. 2008
    ..Our discussion addresses a recent clinical vaccine trial to treat early breast cancer, where many elements of this new strategy were put into practice...
  9. ncbi Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor
    J Kjaergaard
    Center for Surgery Research and Lerner Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Immunol 167:6669-77. 2001
    ..Our study suggests OX-40R mAb to be a reagent of choice to augment T cell adoptive immunotherapy in clinical trials...
  10. ncbi Tumor-induced L-selectinhigh suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy
    Liaomin Peng
    Center for Surgery Research, Cleveland Clinic Foundation, and Lerner Research Institute, OH 44195, USA
    J Immunol 169:4811-21. 2002
    ....
  11. ncbi Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination
    Hideyuki Kuriyama
    Center for Surgery Research, Cleveland Clinic, Cleveland, OH 44195, USA
    Cell Immunol 243:30-40. 2006
    ..These findings underscore the significance of the third signal in the design of dendritic cell-based cancer vaccines...
  12. ncbi Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors
    G E Plautz
    Center for Surgery Research, The Cleveland Clinic Foundation, OH 44195, USA
    J Immunol 165:3656-62. 2000
    ....
  13. doi Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12
    Rongxiu Zheng
    Center for Surgery Research, Department of Immunology, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Cancer Res 68:4045-9. 2008
    ..These results show the profound functional consequences of TLR cooperativity and further highlight the critical role of IL-12 in antitumor immunity...
  14. ncbi Considerations on clinical use of T cell immunotherapy for cancer
    Gregory E Plautz
    Center for Surgery Research, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Arch Immunol Ther Exp (Warsz) 51:245-57. 2003
    ....
  15. ncbi Therapeutic efficacy of adoptive immunotherapy is predicated on in vivo antigen-specific proliferation of donor T cells
    Jørgen Kjaergaard
    Center for Surgery Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Clin Immunol 108:8-20. 2003
    ..Taken together, our results demonstrate that adoptively transferred T cells undergo extensive proliferation in response to the tumor and this response is associated with therapeutic efficacy...
  16. ncbi Memory T cells originate from adoptively transferred effectors and reconstituting host cells after sequential lymphodepletion and adoptive immunotherapy
    Li Xin Wang
    Center for Surgery Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Immunol 172:3462-8. 2004
    ..These data suggest an approach to rescuing antitumor immune function even in hosts with long-standing progressive tumor through restorative ex vivo activation...
  17. ncbi Formation of nitric oxide-derived oxidants by myeloperoxidase in monocytes: pathways for monocyte-mediated protein nitration and lipid peroxidation In vivo
    S L Hazen
    Department of Cell Biology, Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circ Res 85:950-8. 1999
    ..Collectively, these results demonstrate that monocytes use distinct mechanisms for generating (*)NO-derived oxidants, and they identify MPO as a source of nitrating intermediates in monocytes...
  18. ncbi T cell adoptive immunotherapy of newly diagnosed gliomas
    G E Plautz
    Center for Surgery Research, The Cleveland Clinic Foundation, Ohio 44195, USA
    Clin Cancer Res 6:2209-18. 2000
    ..This Phase I clinical trial of adoptive immunotherapy for patients with newly diagnosed malignant gliomas demonstrates feasibility, lack of long-term toxicity, and several objective clinical responses...
  19. ncbi T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-gamma mechanisms that cannot be predicted from in vitro T cell characteristics
    L Peng
    Center for Surgery Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Immunol 165:7116-24. 2000
    ....
  20. pmc Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species
    E A Podrez
    Department of Cell Biology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Clin Invest 105:1095-108. 2000
    ..MPO secreted from activated phagocytes may also tag phospholipid-containing targets for removal by CD36-positive cells...
  21. ncbi Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion
    Takashi Hayashi
    Center for Surgery Research, Cleveland Clinic Foundation, Ohio 44195, USA
    Clin Immunol 104:14-20. 2002
    ..These results provide an impetus for treating cancer patients with similarly generated cells...
  22. ncbi Therapeutic vaccine generated by electrofusion of dendritic cells and tumour cells
    H Kuriyama
    Center for Surgery Research, The Cleveland Clinic Foundation, Cleveland, Ohio 44185, USA
    Dev Biol (Basel) 116:169-78; discussion 179-86. 2004
    ..The therapeutic efficacy of a DC-tumour fusion vaccine is now being evaluated for the treatment of metastatic melanoma...
  23. ncbi Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients
    Isabelle Bedrosian
    Harrison Department of Surgical Research, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Clin Oncol 21:3826-35. 2003
    ..We evaluated the feasibility, safety, and immunogenicity of mature, peptide-pulsed dendritic cell (DC) vaccines administered by different routes...
  24. ncbi Adenovirus type 5 vectors induce dendritic cell differentiation in human CD14(+) monocytes cultured under serum-free conditions
    Lyudmila A Lyakh
    Regulation of Cell Growth Laboratory, The Laboratory of Experimental Immunology, and the Mouse Cancer Genetics Program, National Cancer Institute at Frederick, MD 21702 1201, USA
    Blood 99:600-8. 2002
    ..These findings have implications for the biology of monocytes as precursors to DCs and also for the use of recombinant adenovirus in vaccines or gene therapy...
  25. ncbi Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived Peptide epitopes
    Walter J Storkus
    Department of Dermatology, University of Pittsburgh School of Medicine, PA 15213, USA
    Crit Rev Immunol 27:485-93. 2007
    ..This may facilitate the design and performance of novel combinational therapies for the effective treatment of a broad range of cancer types...
  26. ncbi Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism
    Shuwen Xu
    Harrison Department of Surgical Research, Department of Surgery, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
    J Immunol 171:2251-61. 2003
    ..A new approach to DC-based vaccines that emphasizes IL-12 secretion to enhance functional avidity and concomitant tumor recognition by CD8+ T cells is indicated...
  27. ncbi Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion
    Brian J Czerniecki
    Department of Surgery, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Cancer Res 67:1842-52. 2007
    ..DC1 vaccination strategies may therefore have potential for both the prevention and the treatment of early breast cancer...
  28. ncbi Cutting edge: innate immune system discriminates between RNA containing bacterial versus eukaryotic structural features that prime for high-level IL-12 secretion by dendritic cells
    Gary K Koski
    Harrison Department of Surgical Research, Department of Surgery, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Immunol 172:3989-93. 2004
    ..RNA structured to emulate bacterial patterns constitutes a novel vaccine strategy to engender polarized Th1-type immune responses...

Research Grants2

  1. PROLIFERATIVE CONDITIONING OF TUMOR-COMPETENT DENDRITIC CELL PRECURSORS
    Peter Cohen; Fiscal Year: 2007
    ..This project aims to provide the information needed to bring this research to a clinical trial for treating cancer patients. ..